Abbott Diagnostics Doubles Down on China with Local Launch of Alinity i and GLP Automation Systems

Abbott announced itsChina-produced Immunoassay Module Alinity iAndAutomated Pipeline GLPOfficially launched,A New Chapter of Localized Production of These Two Intelligent Solutions in Abbott Diagnostics' Hangzhou FactoryIn the future, the innovative diagnosis and treatment resources of "Made in China" will cover more regions, helping to cultivate new quality productivity in the medical field.

In recent years, with the continuous development of smart healthcare and precision medicine, laboratory medicine is gradually transforming from a "data production base" within hospitals to a "medical decision-making engine" for clinical diagnosis and treatment. By closely integrating with clinical work, it enhances the accuracy of medical decisions and the overall quality of healthcare services. Continuously optimizing testing processes to achieve efficient and precise testing has become the direction for medical laboratories to better support clinical departments in making more accurate and personalized medical decisions.

Address by Chen Ying, Global Vice President of Abbott Core Diagnostics

Shen Yanjun (left), Deputy Secretary of the Qiantang New Area Working Committee and Director of the Management Committee, Deputy Secretary of the District Party Committee and District Governor of Hangzhou City, Zhejiang Province, poses for a photo with Chen Ying (right), Global Vice President of Abbott Core Diagnostics.

With the support of the Zhejiang Provincial Government,The Alinity i China production project took only nine months from official initiation to approval, and it has also become the first imported medical device project localized in Hangzhou.Its production plant is the Abbott Diagnostics Hangzhou factory, one of Abbott's four factories in China. As the largest base for research, development, and production of immunochromatographic in vitro diagnostic reagents globally for Abbott, the Abbott Diagnostics Hangzhou factory covers a wide range of product lines, with an annual market supply of approximately 500 million tests, providing products to over 100 countries and regions worldwide.

Abbott Diagnostics Hangzhou Plant

Alinity i is the first product in the Alinity family series of solutions to be launched in China.Effectively enhance the operational efficiency and high-quality development of laboratories; The GLP laboratory automation system meets the growing needs of laboratories from multiple dimensions, such as improving sample turnaround time, ensuring accurate clinical decision-making, reducing staff workload, and making full use of space.

Abbott Diagnostics Immunoassay Module Alinity i

Automated Pipeline GLP

Moreover, to better support the development of China's healthcare industry, while continuously advancing localized production, Abbott will also increase its investment in the cultivation of local medical talent and the transformation of local medical innovation. Through the Abbott Diagnostics Academy, in collaboration with industry associations and experts, Abbott will create a customized, empowering, and forward-looking academic exchange platform to enhance and empower the overall professional capabilities of medical talents. Relying on the Abbott Translational Science Academy, Abbott will build a collaborative platform for government, industry, academia, research, and medical sectors, bridging clinical and industrial communication, empowering the training of interdisciplinary technical talents, and promoting the establishment of a local innovation ecosystem.

[1] Wu Mei, Zhu Jingjing. The First Imported Medical Device Localization Project in Hangzhou Takes Off [N]. Hangzhou Daily, 2024.09.10(A14).

To facilitate communication and exchange among the readers and fans of the In Vitro Diagnostics Network, we have specially established the 157th In Vitro Diagnostics Network group in China! Everyone is welcome to scan the QR code below and join the group to participate actively in discussions!